Nivolumab and DAY101 for Treatment of Craniopharyngioma in Children and Young Adults

Conditions:   Craniopharyngioma, Child;   Craniopharyngioma;   Recurrent Craniopharyngioma Interventions:   Drug: Nivolumab;   Drug: DAY101 Sponsors:   Sabine Mueller, MD, PhD;   Bristol-Myers Squibb;   Day One Biopharmaceuticals, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials